Clinical validation of EMBER. Credit: npj Breast Cancer (2024). DOI: 10.1038/s41523-024-00665-z Addressing problems with diagnosing and treating breast cancer, scientists at EPFL have developed EMBER, a tool that integrates breast cancer transcriptomic data from multiple databases. EMBER can improve precision oncology by accurately predicting molecular subtypes and therapy responses. Breast cancer is the most frequently diagnosed cancer worldwide. However, it is not a uniform disease; it comes in different subtypes, which need to be accurately identified for doctors to effectively tailor treatments to individual patients. Cancer subtyping has traditionally been performed with histological staining (immunohistochemistry), which visually identifies specific markers Read More
No comments:
Post a Comment